154 results on '"Gillmore, Roopinder"'
Search Results
2. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
3. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
4. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
5. Predictive multi-omics analysis of BPM31510 in combination with gemcitabine in a phase 2 study of advanced pancreatic ductal adenocarcinoma (PDAC).
6. 2632: SBRT for Hepatocellular Carcinoma: Real World Outcomes After National Commissioning in England
7. Studies of the Wilms' tumour 1 gene in patients with solid tumours
8. Clinical experience with pemigatinib for previously treated metastatic cholangiocarcinoma: practical considerations from clinical cases
9. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
10. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
11. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
12. Gene Therapy for Prostate Cancer
13. Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC).
14. Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival
15. Neurological symptoms from a brain metastasis as the first presentation of colorectal cancer
16. Peritoneal lymphomatosis: a rare presentation of follicular lymphoma mimicking peritoneal carcinomatosis
17. Bilateral extraocular muscle (EOM) metastases from adenocarcinoma of the gastro-oesophageal junction (GOJ)
18. A rare cause of susceptibility to neutropenic sepsis in a patient with metastatic pancreas cancer
19. Systemic lupus erythematosus mimicking lymphoma: the relevance of the clinical background in interpreting imaging studies
20. Metastatic breast cancer and monoclonal gammopathy of undetermined significance resembling multiple myeloma.
21. Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors' reply
22. IMPACT OF A CANCER OF UNKNOWN PRIMARY (CUP) SERVICE ON END OF LIFE PLANNING FOR PATIENTS WITH METASTATIC DISEASE
23. ULBP1 Is Elevated in Human Hepatocellular Carcinoma and Predicts Outcome
24. Phase II trial of BPM31510-IV plus gemcitabine in advanced pancreatic ductal adenocarcinomas (PDAC).
25. FOLFOX as Second-Line Chemotherapy for Advanced Biliary Tract Cancer
26. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene–transduced human T cells
27. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial
28. WT1 as target for tumor immunotherapy
29. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma : A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial
30. Chemotherapy for trophoblastic disease: current standards
31. Chemotherapy for trophoblastic disease: current standards
32. Metastatic bone disease from an occult renal primary
33. Routine terminations of pregnancy -- should we screen for gestational trophoblastic neoplasia?
34. Endometriosis: a rare cause of multiple lung nodules on imaging
35. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4) : a multicentre, open-label, randomised, phase 3 trial
36. Oncology admissions to the intensive care unit: what factors should influence the decision?
37. The workload and impact of a dedicated cancer of unknown primary (CUP) service on patients with imaging suggestive of metastatic disease
38. A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (mPDAC).
39. Outcomes and prognostic markers of patients admitted to intensive care: A six-year analysis
40. Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours
41. STAR_PAC: A Phase 1B study repurposing ATRA as stromal targeting agent along with gemcitabine and nab¬Paclitaxel for pancreatic cancer
42. ABC-12: Exploring the microbiome in patients (pts) with advanced biliary tract cancer (BTC) in a first-line study of durvalumab in combination with cisplatin/gemcitabine (cis/gem).
43. Pseudoaneurysm development after stenting for malignant biliary obstruction
44. Dark macules in the upper gastrointestinal tract: An ominous sign
45. P-165 - The workload and impact of a dedicated cancer of unknown primary (CUP) service on patients with imaging suggestive of metastatic disease
46. Gene Therapy for Prostate Cancer
47. Impact of a cancer of unknown primary (CUP) service on end-of-life planning for patients with metastatic cancer.
48. Oxaliplatin/5-fluorouracil in advanced hepatocellular carcinoma: case report and single-center retrospective review
49. The Impact of Folfirinox Chemotherapy on the Treatment Pattern of Patients with Pancreas Cancer Seen at a Tertiary Referral Centre in the UK
50. Significance of alterations in DNA damage repair (DDR) genes in advanced biliary cancers (ABCs) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III,...
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.